Biotech Vertex Pharmaceuticals is confirmed to be one of the most promising companies in the sector. YTD Vertex’s shares (Nasdaq) rose by 18% and, according to many analysts, they can only grow further. Yesterday, during a press release, the company announced that the European Commission granted approval of the label extension for Orkambi (lumacaftor/ivacaftor) to treat children with cystic fibrosis aged 2 to 5 years old who are homozygous for the F508del mutation. Orkambi has already been approved in Europe to treat cystic fibrosis in patients over 6 years old.
Vertex is the undisputed leader in treatments for cystic fibrosis, and it regularly impresses the market with better-than-expected outcomes.
Vertex’s pipeline boasts a number of new therapeutic solutions to treat cystic fibrosis. Nonetheless, it also markets VX150 for osteoarthritis-related acute pain relief, which could help boost the company’s product differentiation. Moreover, the group relies on solid financial assets, with cash flows over $900m (Q3 2018) and $1,1bn liquid assets. Last but not least, according to many, Vertex could very soon complete a big takeover.